Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888227 | 0.88 | POLB (0.42) | POLBP2RX3P2RX4P2RX2P2RX1 | |
| SCHEMBL888102 | 0.86 | ENPP1 (0.54) | POLBP2RY1ENPP1 | |
| SCHEMBL888156 | 0.85 | POLB (0.48) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL1140777 | 0.80 | POLB (0.47) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL30848930 | 0.80 | P2RX3 (0.53) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL21564046 | 0.80 | P2RX3 (0.53) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL888089 | 0.80 | P2RX3 (0.53) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL14665951 | 0.80 | P2RX3 (0.53) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL888262 | 0.80 | P2RX3 (0.53) | POLBP2RX3P2RX4P2RX7P2RX2 | |
| SCHEMBL888149 | 0.80 | POLB (0.45) | POLBP2RX3P2RX4P2RX2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | POLB 28/4885P2RX3 1152/4885P2RX4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.